Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.

Dorneles G, Algeri E, Lauterbach G, Pereira M, Fernandes B

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association10 Apr 2024Cited by 2 (Europe PMC)

PMID38599612DOI10.1055/a-2303-8558PepBankPUB-38599612

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewEfficacy outcome
In overweight or obese adults, once-weekly semaglutide decreased relative body weight (MD -11.80, 95% CI -13.53 to -10.07; high certainty).
In plain wordsIn overweight or obese adults, once-weekly semaglutide lowered relative body weight in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
DecreaseRelative body weight
Study
n = 22,155
Outcome group
Body weight · Metabolic and weight
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
MD relative body weight
−11.8
semaglutide
Source sentences
Summary
Semaglutide decreased relative body weight (MD: -11.80; 95%CI: -13.53 to -10.07; CoE: High)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961201
02HumanSystematic reviewEfficacy outcome
In overweight or obese adults, once-weekly semaglutide decreased absolute body weight (MD -11.58, 95% CI -13.25 to -9.90; high certainty).
In plain wordsIn overweight or obese adults, once-weekly semaglutide lowered absolute body weight in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
DecreaseAbsolute body weight
Study
n = 22,155
Outcome group
Body weight · Metabolic and weight
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
MD absolute body weight
−11.58
semaglutide
Source sentences
Summary
absolute body weight (MD: -11.58; 95%CI: -13.25 to -9.90; CoE: High)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961202
03HumanSystematic reviewEfficacy outcome
In overweight or obese adults, once-weekly semaglutide decreased BMI (MD -4.15, 95% CI -4.85 to -3.45; high certainty).
In plain wordsIn overweight or obese adults, once-weekly semaglutide lowered body mass index in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
DecreaseBody mass index
Study
n = 22,155
Outcome group
Body weight · Metabolic and weight
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
MD BMI
−4.15
semaglutide
Source sentences
Summary
and BMI (MD: -4.15; 95%CI: -4.85 to -3.45; CoE: High)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961203
04HumanSystematic reviewEfficacy outcome
In overweight or obese adults, semaglutide increased the proportion with weight loss of 5% or more (RR 2.29, 95% CI 1.88 to 2.80).
In plain wordsIn overweight or obese adults, more people lost at least 5% of their weight with semaglutide in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 5% or more
Study
n = 22,155
Outcome group
Body weight · Metabolic and weight
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
RR weight loss 5% or more
2.29
semaglutide
Source sentences
Summary
Semaglutide also increased the proportion of patients who achieved 5%, 10%, and 15% of weight loss ([weight loss≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961204
05HumanSystematic reviewEfficacy outcome
In overweight or obese adults, semaglutide increased the proportion with weight loss of 10% or more (RR 4.54, 95% CI 3.45 to 5.98).
In plain wordsIn overweight or obese adults, more people lost at least 10% of their weight with semaglutide in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 10% or more
Study
n = 22,155
Outcome group
Body weight · Metabolic and weight
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
RR weight loss 10% or more
4.54
semaglutide
Source sentences
Summary
Semaglutide also increased the proportion of patients who achieved 5%, 10%, and 15% of weight loss ([weight loss≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961205
06HumanSystematic reviewEfficacy outcome
In overweight or obese adults, semaglutide increased the proportion with weight loss of 15% or more (RR 8.29, 95% CI 5.54 to 12.39).
In plain wordsIn overweight or obese adults, more people lost at least 15% of their weight with semaglutide in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 15% or more
Study
n = 22,155
Outcome group
Body weight · Metabolic and weight
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
RR weight loss 15% or more
8.29
semaglutide
Source sentences
Summary
Semaglutide also increased the proportion of patients who achieved 5%, 10%, and 15% of weight loss ([weight loss≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961206
07HumanSystematic reviewSafety outcome
In overweight or obese adults, semaglutide was linked to a small increase in the risk of adverse events (RR 1.03, 95% CI 1 to 1.06; high certainty).
In plain wordsIn overweight or obese adults, semaglutide was linked to a small rise in the risk of any side effect.
Peptide
Semaglutide
Outcome
IncreaseAny adverse events
Study
n = 22,155
Outcome group
Adverse events · Whole body
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
RR adverse events
1.03
semaglutide
Source sentences
Summary
Semaglutide leads to small risk to adverse events (RR: 1.03; 95%CI: 1 to 1.06; CoE: High)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961207
08HumanSystematic reviewSafety outcome
In overweight or obese adults, semaglutide showed no difference in serious adverse events (RR 1.07, 95% CI 0.70 to 1.62; low certainty).
In plain wordsIn overweight or obese adults, serious side effects were not different with semaglutide in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events
Study
n = 22,155
Outcome group
Adverse events · Whole body
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
RR serious adverse events
1.07
semaglutide
Source sentences
Summary
no difference in the serious adverse events (RR: 1.07; 95%CI: 0.70 to 1.62; CoE: Low)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961208
09HumanSystematic reviewSafety outcome
In overweight or obese adults, semaglutide increased the risk of discontinued treatment (RR 2.03, 95% CI 1.87 to 2.20; high certainty).
In plain wordsIn overweight or obese adults, more people stopped treatment with semaglutide in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
IncreaseTreatment discontinuation
Study
n = 22,155
Outcome group
Adverse events · Whole body
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
RR discontinued treatment
2.03
semaglutide
Source sentences
Summary
but increases in the risk to discontinued treatment (RR: 2.03; 95%CI: 1.87 to 2.20; CoE: High)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961209
10HumanSystematic reviewSafety outcome
In overweight or obese adults, semaglutide increased the risk of gastrointestinal adverse events (RR 3.26, 95% CI 1.99 to 5.34; moderate certainty).
In plain wordsIn overweight or obese adults, semaglutide raised the risk of stomach and gut side effects in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 22,155
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
once-weekly · subcutaneousAs given in this study (human).
Measurements
RR gastrointestinal adverse events
3.26
semaglutide
Source sentences
Summary
and gastrointestinal adverse events (RR: 3.26; 95%CI: 1.99 to 5.34; CoE: Moderate)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023.
Summary · context
Ten publications, with 22.155 patients, were included.
Report a problemFND-3859961210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.